emicizumab hemophilia
Selected indexed studies
- Emicizumab: the hemophilia A game-changer. (Haematologica, 2024) [PMID:37916312]
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors. (N Engl J Med, 2017) [PMID:28691557]
- Emicizumab for hemophilia A without inhibitors. (Expert Rev Hematol, 2019) [PMID:31130012]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Emicizumab: the hemophilia A game-changer. (2024) pubmed
- Emicizumab Prophylaxis in Hemophilia A with Inhibitors. (2017) pubmed
- Emicizumab for hemophilia A without inhibitors. (2019) pubmed
- Hemophilia A: Emicizumab monitoring and impact on coagulation testing. (2023) pubmed
- Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. (2018) pubmed
- Outcomes of Emicizumab in Acquired Hemophilia Patients: A Systematic Review. (2024) pubmed
- Long-term outcomes with emicizumab prophylaxis for hemophilia A with or without FVIII inhibitors from the HAVEN 1-4 studies. (2021) pubmed
- Emicizumab for the Treatment of Acquired Hemophilia A: Consensus Recommendations from the GTH-AHA Working Group. (2024) pubmed
- Emicizumab prophylaxis in infants with hemophilia A (HAVEN 7): primary analysis of a phase 3b open-label trial. (2024) pubmed
- Acquired hemophilia A: a narrative review and management approach in the emicizumab era. (2025) pubmed